This database contains 160 studies, archived under the term: "Background"
Click here to filter this large number of results.
Dietary intake of vitamin D and cognition in older women: a large population-based study
Annweiler, C.,
Schott, A.M.,
Rolland, Y.,
Blain, H.,
Herrmann, F. R.,
Beauchet, O.
Background: Serum vitamin D concentrations are associated with global cognitive function among older adults. The benefits of vitamin D intake to treat or prevent cognitive impairment remain unknown. The objective of this cross-sectional study was to determine whether weekly dietary intake of vitamin D could be associated with global cognitive performance among older adults.; Methods: […]
Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study
Annweiler, C.,
Rolland, Y.,
Schott, A.M.,
Blain, H.,
Vellas, B.,
Beauchet, O.
Background: Hypovitaminosis D has been cross-sectionally associated with dementia and stroke. The objective of this longitudinal study was to determine whether serum vitamin D deficiency at baseline could predict the onset of non-Alzheimer dementias (NAD) within 7 years among older women.; Methods: Forty high-functioning older women (78.4 years, 76.4/82.0; median, 25th/75th percentile) from the EPIDOS […]
Exergaming and older adult cognition: a cluster randomized clinical trial
Anderson-Hanley, Cay,
Arciero, Paul J.,
Brickman, Adam M.,
Nimon, Joseph P.,
Okuma, Naoko,
Westen, Sarah C.,
Merz, Molly E.,
Pence, Brandt D.,
Woods, Jeffrey A.,
Kramer, Arthur F.,
Zimmerman, Earl A.
Background: Dementia cases may reach 100 million by 2050. Interventions are sought to curb or prevent cognitive decline. Exercise yields cognitive benefits, but few older adults exercise. Virtual reality-enhanced exercise or “exergames” may elicit greater participation.; Purpose: To test the following hypotheses: (1) stationary cycling with virtual reality tours (“cybercycle”) will enhance executive function and […]
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies
Anderson, Craig,
Teo, Koon,
Gao, Peggy,
Arima, Hisatomi,
Dans, Antonio,
Unger, Thomas,
Commerford, Patrick,
Dyal, Leanne,
Schumacher, Helmut,
Pogue, Janice,
Paolasso, Ernesto,
Holwerda, Nicolaas,
Chazova, Irina,
Binbrek, Azan,
Young, James,
Yusuf, Salim
Background: cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.; Methods: in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, […]
Supervised exercise to reduce agitation in severely cognitively impaired persons
Background: Several studies have shown an improvement in depression, activities of daily living, and agitation in cognitively impaired subjects who undergo a long-term exercise program. These studies have not considered the short-term effects of exercise.; Objectives: The purpose of this study was to investigate the short-term effects of a limited, supervised exercise program on agitation, […]
Cognitive dysfunction in SLE: development of a screening tool
Background: Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.; Purpose: The […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]